Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00746954 · ClinicalTrials.gov registry record · Phase 3
Buspirone as a Potential Treatment for Recurrent Central Apnea
A Phase 3 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT00746954: Clinical Trial Phase 3 study, sponsored by VA Office of Research and Development.
NCT00746954 is a Phase 3 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00746954, a Phase 3 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether buspirone compared to acetazolamide and to placebo will reduce the number and/or severity of breathing pauses during sleep that occur in some patients with Heart Failure.
Interventions
- DRUG Acetazolamide
- DRUG Buspirone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00746954
The ClinicalTrials.gov registry entry for NCT00746954 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Acetazolamide is the first listed.
NCT00746954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00746954 about?
NCT00746954 is a clinical study titled "Buspirone as a Potential Treatment for Recurrent Central Apnea". The purpose of this study is to determine whether buspirone compared to acetazolamide and to placebo will reduce the number and/or severity of breathing pauses during sleep that occur in some patients with Heart Failure.
What is the current status of trial NCT00746954?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2008-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00746954?
The interventions under investigation include: Acetazolamide (DRUG), Buspirone (DRUG).
Who is sponsoring clinical trial NCT00746954?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.